左旋米唑联合丹参腹腔化疗在消化系癌术后的早期应用  

The early application of Levamisole(LMS)and Radix Salviae Miltiorrhizae(RSM)in peritoneal cavity chemical therapy after operation of the digestion system cancer

作　　者：贺咏宁[1] 司小刚[1] 贺长春[1] 康贻淦[1] 

机构地区：[1]井冈山学院医学院附属医院普外科,江西吉安343000

出　　处：《井冈山学院学报（综合版）》2005年第12M期102-104,106,共4页Journal of Jinggangshan University

摘　　要：目的探讨左旋米唑联合丹参腹腔化疗在消化系癌术后早期应用的临床效果。方法对2001年6月- 2005年6月收治的98例消化系癌进行分组,治疗组50例,对照组48例。其中治疗组为左旋米唑联合丹参腹腔化疗,对照组不用左旋米唑及丹参。结果两组进行比较,治疗组的并发症减少,毒副反应变轻,生存率增高,复发率降低。结论消化系癌术后早期行左旋米唑联合丹参腹腔化疗,不仅是安全可行的,而且毒副反应小,并发症少,近期疗效满意,是一项很有发展前景的治疗方法。Objective： Discuss the effects of the early application of Levamisole （LMS） and Radix Salviae Miltiorrhizae （RSM） in peritoneal cavity chemical therapy after the digestion system cancer operation. Methods： Grouping the 98 cases of the digestion system cancer. 50 cases in therapy group, 48 cases in comparative group. LMS and RSM in peritoneal cavity chemical therapy is used in therapy group, while without LMS and RSM in comparative group. Results： Comparing the two groups, in therapy group, less complicating diseases, less poisonous side effects, living rate raises and recrudescence rate reduces. Conclusions： The early application of LMS and RSM in peritoneal cavity chemical therapy after the digestion system cancer operation is not only doable, but also less complicating diseases and poisonous side effects. The recent effects are satisfied, and it is a very prospective therapy.

关 键 词：消化道肿瘤 手术后 腹腔化疗 丹参 左旋米唑 

分 类 号：R730.53[医药卫生—肿瘤]